Year All202620252024202320222021202020192018201720162014201320112010 October 31, 2017 Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome October 10, 2017 Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares October 4, 2017 Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering August 1, 2017 Rhythm Expands Executive Leadership Team June 27, 2017 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity May 17, 2017 Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity May 11, 2017 Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity May 4, 2017 Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity April 11, 2017 Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors February 16, 2017 Rhythm Announces Completion of $41 Million Mezzanine Financing
October 31, 2017 Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
October 10, 2017 Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 27, 2017 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
May 17, 2017 Rhythm Expands Phase 2 Clinical Trials of Setmelanotide to the Treatment of Bardet-Biedl Syndrome Obesity
May 11, 2017 Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity
May 4, 2017 Rhythm Starts Phase 3 Clinical Trial of Setmelanotide for Rare Genetic Disorder of Obesity
April 11, 2017 Rhythm Appoints Head of Sanofi Genzyme, Dr. David Meeker, as Chairman of Board of Directors
